Filtered By:
Cancer: Ovarian Cancer
Education: Study

This page shows you your search results in order of date. This is page number 19.

Order by Relevance | Date

Total 485 results found since Jan 2013.

Follicle-stimulating hormone peptide-conjugated nanoparticles for targeted shRNA delivery lead to effective gro- α silencing and antitumor activity against ovarian cancer.
In conclusion, gro-α shRNA-loaded nanoparticles conjugated with FSH peptides overcame the drawbacks of the in vivo application of RNAi therapeutics and polymer-based nanocarriers and showed safe antitumor efficacy. Our study might contribute to the application of FSHR-based targeted therapy and imaging in cancer. PMID: 29461120 [PubMed - as supplied by publisher]
Source: Drug Delivery - February 22, 2018 Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research

Valproic Acid Promotes Apoptosis and Cisplatin Sensitivity Through Downregulation of H19 Noncoding RNA in Ovarian A2780 Cells.
Abstract Cisplatin resistance is one of the main limitations in the treatment of ovarian cancer, which is partly mediated by long noncoding RNAs (lncRNAs). H19 is a lncRNA involving in cisplatin resistance in cancers. Valproic acid (VPA) is a commonly used drug for clinical treatment of seizure disorders. In addition, this drug may display its effects through regulation of noncoding RNAs controlling gene expression. The aim of the present study was the investigation of VPA treatment effect on H19 expression in ovarian cancer cells and also the relation of the H19 levels with apoptosis and cisplatin resistance. Bri...
Source: Applied Biochemistry and Biotechnology - February 22, 2018 Category: Biochemistry Authors: Sajadpoor Z, Amini-Farsani Z, Teimori H, Shamsara M, Sangtarash MH, Ghasemi-Dehkordi P, Yadollahi F Tags: Appl Biochem Biotechnol Source Type: research

In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor- κB signaling pathway.
In vitro study on reversal of ovarian cancer cell resistance to cisplatin by naringin via the nuclear factor-κB signaling pathway. Exp Ther Med. 2018 Mar;15(3):2643-2648 Authors: Zhu H, Gao J, Wang L, Qian KJ, Cai LP Abstract The aim of the present study was to investigate the mechanism of action by which naringin reverses the resistance of ovarian cancer cells to cisplatin. Semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) and western blotting assays were used to detect the effects of different concentrations of naringin on the expressions of nuclear factor (NF)-κB and P-gly...
Source: Experimental and Therapeutic Medicine - February 21, 2018 Category: General Medicine Tags: Exp Ther Med Source Type: research

Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
In this study we aimed to identify mechanisms of resistance to SRC inhibitors in ovarian cancer cells. Using two complementary strategies; a targeted tumour suppressor gene siRNA screen, and a phospho-receptor tyrosine kinase array, we demonstrate that activation of MAPK signalling, via a reduction in NF1 (neurofibromin) expression or overexpression of HER2 and the insulin receptor, can drive resistance to AZD0530. Knockdown of NF1 in two ovarian cancer cell lines resulted in resistance to AZD0530, and was accompanied with activated MEK and ERK signalling. We also show that silencing of HER2 and the insulin receptor can pa...
Source: Oncotarget - February 14, 2018 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
CONCLUSION: ROR1 and ROR2 play distinct roles in endometrial cancer. ROR1 may promote tumor progression, similar to its role in ovarian cancer, while ROR2 may act as a tumor suppressor in endometrioid endometrial cancer, similar to its role in colorectal cancer. With several ROR-targeting therapies currently in development and phase I clinical trials for other tumor types, this study supports the potential of these receptors as therapeutic targets for women with endometrial cancer. PMID: 29395309 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Henry CE, Llamosas E, Daniels B, Coopes A, Tang K, Ford CE Tags: Gynecol Oncol Source Type: research

Downregulation of Annexin A11 (ANXA11) Inhibits Cell Proliferation, Invasion, and Migration via the AKT/GSK-3 β Pathway in Gastric Cancer.
CONCLUSIONS ANXA11 plays a critical role in regulating GC proliferation, migration, and invasion via the AKT/GSK-3β pathway, and can potentially be used as a prognostic factor and therapeutic target for gastric cancer patients. PMID: 29306955 [PubMed - in process]
Source: Medical Science Monitor - January 8, 2018 Category: Research Tags: Med Sci Monit Source Type: research

Goserelin promotes the apoptosis of epithelial ovarian cancer cells by upregulating forkhead box  O1 through the PI3K/AKT signaling pathway.
In conclusion, our data suggested that goserelin may promote EOC cell apoptosis by upregulating FOXO1 through the PI3K/AKT signaling pathway. We believe that GnRH agonists may be potential antitumor agents, and key factors in the PI3K/AKT-FOXO1 pathway may also be novel therapeutic targets for the treatment of EOC. PMID: 29286125 [PubMed - as supplied by publisher]
Source: Oncology Reports - December 30, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Iloprost, a prostacyclin analog, inhibits the invasion of ovarian cancer cells by downregulating matrix metallopeptidase-2 (MMP-2) through the IP-dependent pathway
This study investigated the effects of PGI2 on cell growth, migration, and invasion in ovarian cancer cells using iloprost, a stable PGI2 analog. Iloprost significantly inhibited migration and invasion, but not cell growth, in a dose-dependent manner in human ovarian cancer cells (A2780 and SKOV3). Interestingly, the cell surface Gs protein-coupled PGI2 receptor IP was enhanced in human ovarian cancer cells. The inhibitory effect of iloprost on migration and invasion was entirely reversed by an IP antagonist (CAY10449) and IP siRNA, whereas the knockdown of peroxisome proliferator-activated receptor δ (PPARδ), a nuclear ...
Source: Prostaglandins and Other Lipid Mediators - December 30, 2017 Category: Lipidology Source Type: research

Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance
The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance in ovarian cancer is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer. Mechanistically, LPP increased focal adhesion and stress fiber formation to promote endothelial cell motil...
Source: Journal of Clinical Investigation - December 19, 2017 Category: Biomedical Science Authors: Cecilia S. Leung, Tsz-Lun Yeung, Kay-Pong Yip, Kwong-Kwok Wong, Samuel Y. Ho, Lingegowda S. Mangala, Anil K. Sood, Gabriel Lopez-Berestein, Jianting Sheng, Stephen T.C. Wong, Michael J. Birrer, Samuel C. Mok Source Type: research

Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells
This study investigated the effects of SALL2 on human ovarian carcinoma (OC) A2780 cells and the probable mechanism.
Source: BMC Cancer - December 11, 2017 Category: Cancer & Oncology Authors: Fang Miao, Xueshan Zhang, Yanning Cao, Yue Wang and Xiaoshu Zhang Tags: Research article Source Type: research

Identification of Estrogen-Related Receptor Alpha Agonists in the Tox21 Compound Library.
This study is the first comprehensive analysis in discovering potential endocrine disrupters which affect the ERRα signaling pathway. PMID: 29216352 [PubMed - as supplied by publisher]
Source: Endocrinology - December 4, 2017 Category: Endocrinology Authors: Lynch C, Zhao J, Huang R, Kanaya N, Bernal L, Hsieh JH, Auerbach SS, Witt KL, Merrick BA, Chen S, Teng CT, Xia M Tags: Endocrinology Source Type: research

Clinical significance and biological role of Wnt10a in ovarian cancer.
Authors: Li P, Liu W, Xu Q, Wang C Abstract Ovarian cancer is one of the five most malignant types of cancer in females, and the only currently effective therapy is surgical resection combined with chemotherapy. Wnt family member 10A (Wnt10a) has previously been identified to serve an oncogenic function in several tumor types, and was revealed to have clinical significance in renal cell carcinoma; however, there is still only limited information regarding the function of Wnt10a in the carcinogenesis of ovarian cancer. The present study identified increased expression levels of Wnt10a in two cell lines, SKOV3 and A2...
Source: Oncology Letters - November 24, 2017 Category: Cancer & Oncology Tags: Oncol Lett Source Type: research

Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin
AbstractHigh-temperature-required protein A2 (HtrA2) is one of the serine proteases related to apoptosis. HtrA2 protein expression has been associated with cisplatin resistance and poor prognosis in ovarian serous adenocarcinoma (SAC). The aim of this study was to understand the influence of HtrA2 on repeated treatment with cisplatin. The change in HtrA2 expression in 31 ovarian cancers was investigated by immunohistochemical analysis, before and after cisplatin-based chemotherapy, and the association between HtrA2 expression after chemotherapy and prognosis was analyzed. The association between the change in HtrA2 and pro...
Source: Medical Oncology - November 22, 2017 Category: Cancer & Oncology Source Type: research

Placenta-specific protein 1 promotes cell proliferation and invasion in non-small cell lung cancer.
Authors: Yang L, Zha TQ, He X, Chen L, Zhu Q, Wu WB, Nie FQ, Wang Q, Zang CS, Zhang ML, He J, Li W, Jiang W, Lu KH Abstract Pulmonary carcinoma-associated proteins have emerged as crucial players in governing fundamental biological processes such as cell proliferation, apoptosis and metastasis in human cancers. Placenta-specific protein 1 (PLAC1) is a cancer-related protein, which is activated and upregulated in a variety of malignant tissues, including prostate cancer, gastric adenocarcinoma, colorectal, epithelial ovarian and breast cancer. However, its biological role and clinical significance in non-small cell...
Source: Oncology Reports - November 16, 2017 Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

β-Catenin Cooperates with CREB Binding Protein to Promote the Growth of Tumor Cells
Conclusions: Our study has provided new evidence for the role of β-catenin in promoting the growth of lung cancer cells through cooperation with CBP, and suggested that dual targeting of β-catenin and CBP could be a potential therapeutic strategy in lung cancer treatment.Cell Physiol Biochem 2017;44:467 –478
Source: Cellular Physiology and Biochemistry - November 15, 2017 Category: Cytology Source Type: research